tradingkey.logo

Quantum BioPharma Ltd

QNTM
4.200USD
+0.280+7.14%
Cierre 02/06, 16:00ETCotizaciones retrasadas 15 min
16.03MCap. mercado
PérdidaP/E TTM

Quantum BioPharma Ltd

4.200
+0.280+7.14%

Más Datos de Quantum BioPharma Ltd Compañía

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Información de Quantum BioPharma Ltd

Símbolo de cotizaciónQNTM
Nombre de la empresaQuantum Biopharma Ltd
Fecha de salida a bolsaMay 29, 2018
Director ejecutivoKotra (Lakshmi P)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 29
Dirección55 University Ave. , Suite 1003
CiudadTORONTO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalM5J 2H7
Teléfono14168548884
Sitio Webhttps://www.quantumbiopharma.com/
Símbolo de cotizaciónQNTM
Fecha de salida a bolsaMay 29, 2018
Director ejecutivoKotra (Lakshmi P)

Ejecutivos de Quantum BioPharma Ltd

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+300.00%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+7692.00%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
29.11K
-77647.00%
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--
Mr. Joseph L. Romano
Mr. Joseph L. Romano
Director
Director
--
--
Dr. Eric Hoskins, M.D.
Dr. Eric Hoskins, M.D.
Independent Director
Independent Director
--
--
Mr. Michael (Zappy) Zapolin
Mr. Michael (Zappy) Zapolin
Independent Director
Independent Director
--
--
Dr. Andrzej Chruscinski, M.D., Ph.D.
Dr. Andrzej Chruscinski, M.D., Ph.D.
Vice President - Clinical and Scientific Affairs
Vice President - Clinical and Scientific Affairs
--
-462.00%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Zeeshan Saeed
Mr. Zeeshan Saeed
Executive Co-Chairman of the Board, President, Chief Executive Officer
Executive Co-Chairman of the Board, President, Chief Executive Officer
118.41K
+300.00%
Mr. Donal Carroll, CPA
Mr. Donal Carroll, CPA
Chief Financial Officer
Chief Financial Officer
90.41K
+7692.00%
Mr. Anthony Durkacz
Mr. Anthony Durkacz
Co-Executive Chairman of the Board
Co-Executive Chairman of the Board
29.11K
-77647.00%
Mr. Lawrence (Larry) Latowsky
Mr. Lawrence (Larry) Latowsky
Independent Director
Independent Director
--
--
Mr. Adnan Bashir
Mr. Adnan Bashir
Independent Director
Independent Director
--
--
Dr. Lakshmi P. Kotra, Ph.D.
Dr. Lakshmi P. Kotra, Ph.D.
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
Chief Executive Officer of Lucid, Director, President of FSD Biosciences and CEO of FSD Australia
--
--

Desglose de ingresos

La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.

Estadísticas de accionistas

Actualizado: vie., 6 de feb
Actualizado: vie., 6 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Malone Wealth Ventures LLC
9.78%
Saeed (Zeeshan)
3.08%
Carroll (Donal)
2.35%
Lynch (Terrence)
1.34%
AdvisorShares Investments, LLC
0.97%
Otro
82.48%
Accionistas
Accionistas
Proporción
Malone Wealth Ventures LLC
9.78%
Saeed (Zeeshan)
3.08%
Carroll (Donal)
2.35%
Lynch (Terrence)
1.34%
AdvisorShares Investments, LLC
0.97%
Otro
82.48%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
11.35%
Individual Investor
8.48%
Corporation
0.37%
Research Firm
0.09%
Otro
79.71%

Participación institucional

Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
42
1.11M
29.06%
+169.60K
2025Q3
40
1.17M
30.70%
+254.90K
2025Q2
50
1.04M
35.99%
+612.85K
2025Q1
50
413.46K
17.05%
-229.58K
2024Q4
44
604.87K
28.35%
+138.76K
2024Q3
45
583.17K
30.09%
+414.87K
2024Q2
43
126.91K
14.87%
-21.03K
2024Q1
47
105.72K
14.06%
-57.49K
2023Q4
49
159.35K
26.32%
+20.22K
2023Q3
52
164.58K
27.23%
+48.13K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Malone Wealth Ventures LLC
1.05M
27.25%
+217.43K
+26.20%
Sep 06, 2025
Saeed (Zeeshan)
118.41K
3.08%
+300.00
+0.25%
Aug 14, 2025
Carroll (Donal)
90.41K
2.35%
+7.69K
+9.30%
Apr 03, 2025
Lynch (Terrence)
51.42K
1.34%
+51.42K
--
Aug 14, 2025
AdvisorShares Investments, LLC
37.24K
0.97%
+247.00
+0.67%
Sep 30, 2025
Kotra (Lakshmi)
29.57K
0.77%
--
--
Aug 14, 2025
Durkacz (Anthony)
29.11K
0.76%
-77.65K
-72.73%
Oct 29, 2025
Marex Group plc
13.44K
0.35%
+13.44K
--
Sep 30, 2025
Saeed (Rehan)
6.79K
0.18%
-2.15K
-24.09%
Dec 31, 2024
Xorax Family Trust
6.79K
0.18%
--
--
Dec 10, 2025
Ver más

ETFs relacionados

Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
AdvisorShares Psychedelics ETF
6.05%
AdvisorShares Psychedelics ETF
Proporción6.05%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
Aug 12, 2024
Merger
65→1
KeyAI